CD163 Dominance Within Macrophages/Microglia Reflects a Favorable Prognosis in Patients With Glioblastoma
Neuropathology · 2026-08 · 46 (4)
DOI: 10.1111/neup.70071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropathology, online erschienen am 16.07.2026. Verfasst von Mayuko Moritsubo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Kurume University School of Medicine, Kurume, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Antigens, Differentiation, Myelomonocytic, Receptors, Cell Surface, Antigens, CD. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Glioblastoma is the most common primary malignant central nervous system (CNS) tumor; however, its microenvironment, including tumor‐associated microglia/macrophages (TAMs), is not fully understood. Although ionized calcium‐binding adaptor molecule 1 (IBA‐1) is expressed in various microglial phenotypes in the healthy human brain, CD163 is a marker of activated/phagocytic microglia. Tissues from 34 patients with glioblastoma were analyzed, and 17.6% of cases were CD163‐dominant. CD163‐dominant patients showed better overall survival than IBA‐1‐dominant patients ( p = 0.019). CD163 dominance was identified as an independent prognostic factor for overall survival (hazard ratio [HR], 0.17; p = 0.011). Compared with the IBA‐1‐dominant group, CD163‐dominant tumors showed more CD4‐positive cell infiltration ( p = 0.005), fewer ameboid TAMs ( p = 0.021), and fewer non‐microvascular proliferation (non‐MVP) vessels ( p = 0.012). No significant differences were found in patient characteristics, such as age, sex, tumor location, or extent of resection. The CD163‐to‐IBA‐1 ratio of TAMs is a significant independent prognostic factor in glioblastoma, suggesting that the activation status of these cells and their interactions with the vascular endothelium and T cells influence tumor progression. These findings highlight TAMs as potential therapeutic targets for glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan.
- Department of Neurosurgery, Kurume University School of Medicine, Kurume, Japan.
ORCID-Profile: Mayuko Moritsubo, Takuya Furuta, Hidenobu Yoshitake, Motohiro Morioka, Hiroaki Miyoshi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Moritsubo, M., Furuta, T., Hashimoto, A., Yoshitake, H., Negoto, T., Nakamura, H., Morioka, M., & Miyoshi, H. (2026). CD163 Dominance Within Macrophages/Microglia Reflects a Favorable Prognosis in Patients With Glioblastoma. Neuropathology, 46(4). https://doi.org/10.1111/neup.70071
Vancouver
Moritsubo M, Furuta T, Hashimoto A, Yoshitake H, Negoto T, Nakamura H, et al. CD163 Dominance Within Macrophages/Microglia Reflects a Favorable Prognosis in Patients With Glioblastoma. Neuropathology. 2026;46(4). doi:10.1111/neup.70071
BibTeX
@article{Moritsubo2026,
author = {Moritsubo, Mayuko and Furuta, Takuya and Hashimoto, Aya and Yoshitake, Hidenobu and Negoto, Tetsuya and Nakamura, Hideo and Morioka, Motohiro and Miyoshi, Hiroaki},
title = {CD163 Dominance Within Macrophages/Microglia Reflects a Favorable Prognosis in Patients With Glioblastoma},
journal = {Neuropathology},
year = {2026},
volume = {46},
number = {4},
doi = {10.1111/neup.70071}
}
EUVIMED